Article PDF
Avoid common mistakes on your manuscript.
References
ES Siris GD Roodman (2003) Paget’s disease of bone MJ Favus (Eds) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism American Society for Bone and Mineral Research Washington DC 495–506
E Siris RS Weinstein R Altman JM Conte M Favus A Lombardi K Lyles H McIlwain WA Murphy SuffixJr C Reda R Rude M Seton R Tiegs D Thompson JR Tucci AJ Yates M Zimering (1996) ArticleTitleComparative study of alendronate vs etidronate for the treatment of Paget s disease of bone. J Clin Endocrinal Metab 81 961–967 Occurrence Handle1:CAS:528:DyaK28Xhs1agsrk%3D
IR Reid GC Nicholson RS Weinstein DJ Hosking T Cundy MA Kotowicz WA Murphy SuffixJr S Yeap S Dufresne A Lombardi TA Musliner DE Thompson AJ Yates (1996) ArticleTitleBiochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo controlled trial. Am J Med 171 341–348
A Lombardi (1999) ArticleTitleTreatment of Paget s disease of bone with alendronate. Bone 24 59S–61S Occurrence Handle1:CAS:528:DyaK1MXjtVGitLg%3D
PL Selby MWJ Davie SH Ralston MD Stone (2002) ArticleTitleGuidelines on the management of Paget s disease of bone. Bone 31 366–373 Occurrence Handle1:STN:280:DC%2BD38vntVCrsg%3D%3D
DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud (1996) ArticleTitleRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535–1541 Occurrence Handle10.1016/S0140-6736(96)07088-2 Occurrence Handle1:CAS:528:DyaK2sXisFCktQ%3D%3D Occurrence Handle8950879
SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix (1998) ArticleTitleEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280 2077–2082 Occurrence Handle1:CAS:528:DyaK1MXjsVWruw%3D%3D
K Kushida M Shiraki T Nakamura H Kishimoto H Morii K Yamamoto K Kaneda M Fukunaga T Inoue M Nakashima H Orimo (2004) ArticleTitleAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow up study. J Bone Miner Metab 22 462–468 Occurrence Handle10.1007/s00774-004-0508-0 Occurrence Handle1:CAS:528:DC%2BD2cXmslCit7c%3D
ES Siris RE Canfield TP Jacobs KE Stoddart PJ Spector (1981) ArticleTitleClinical and biochemical effects of EHDP in Paget’s disease of bone: pattern of response to initial treatment and to long therapy. Metab Bone Dis Relat Res 3 301–308 Occurrence Handle1:STN:280:BiyC28nls10%3D
PD Delmas MC Chapuy E Vignon S Charhon D Briancon C Alexandre C Edouard PJ Meunier (1982) ArticleTitleLong term effects of dichloromethylene diphosphonate in Paget s disease of bone. J Clin Endocrinal Metab 54 837–844 Occurrence Handle1:STN:280:Bi2C2c3ptFw%3D
ST Harris RM Neer GV Segre AJ Petkau GL Tully Suffix3rd M Daly JT Potts SuffixJr (1982) ArticleTitleSecondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget’s disease J Clin Endocrinal Metab 55 1100–1107 Occurrence Handle1:STN:280:BiyD3s7htVM%3D
S Adami N Zamberlan M Mian R Dorizzi M Rossini B Braga D Gatti F Bertoldo V Locascio (1994) ArticleTitleDuration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget s disease of bone. Bone Miner 25 75–82 Occurrence Handle1:CAS:528:DyaK2cXlslSntLk%3D
MEMW Eekhoff AH Zwinderman DMAD Haverkort SCLM Cremers NAT Hamdy SE Papapoulou (2003) ArticleTitleDeterminants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate therapy. Bone 33 831–838 Occurrence Handle10.1016/j.bone.2003.03.001 Occurrence Handle1:CAS:528:DC%2BD3sXovVemt7w%3D
ES Siris (1999) ArticleTitleGoals of treatment for Paget s disease of bone. J Bone Miner Res 14 IssueIDs2 49–52
SA Khan S Vasikaran EV McCloskey MNC Benéton S Rogers L Coulton J Orgee G Coombes JA Kanis (1997) ArticleTitleAlendronate in the treatment of Paget’s disease of bone Bone 20 263–271 Occurrence Handle10.1016/S8756-3282(96)00364-X Occurrence Handle1:CAS:528:DyaK2sXit12qsbw%3D Occurrence Handle9071478
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takada, J., Iba, K. & Yamashita, T. Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget’s disease of bone. J Bone Miner Metab 23, 333–336 (2005). https://doi.org/10.1007/s00774-005-0609-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00774-005-0609-4